Published in Expert Rev Anticancer Ther on October 01, 2008
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer | NCT00542451
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A (2011) 2.14
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
MYC and Breast Cancer. Genes Cancer (2010) 1.66
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res (2009) 1.19
DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. J Clin Invest (2012) 1.18
MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol (2011) 1.15
Enigmatic MYC Conducts an Unfolding Systems Biology Symphony. Genes Cancer (2010) 1.11
Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res (2012) 1.01
Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5. Oncotarget (2013) 1.00
Dynamically regulated miRNA-mRNA networks revealed by exercise. BMC Physiol (2013) 0.97
Nodal signaling promotes a tumorigenic phenotype in human breast cancer. Semin Cancer Biol (2014) 0.97
c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland. BMC Biol (2009) 0.96
Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. PLoS One (2013) 0.94
Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression. Mol Cancer (2010) 0.93
Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency. Oncogene (2011) 0.93
Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis. Breast Cancer Res (2012) 0.91
MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol Cancer (2014) 0.91
Cohesin is required for activation of MYC by estradiol. PLoS One (2012) 0.87
Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer. Curr Cancer Drug Targets (2015) 0.86
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. Am J Cancer Res (2014) 0.84
STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence. Cell Cycle (2016) 0.83
A comparative phosphoproteomic analysis of a human tumor metastasis model using a label-free quantitative approach. Electrophoresis (2010) 0.81
c-Myc is required for proper coronary vascular formation via cell- and gene-specific signaling. Arterioscler Thromb Vasc Biol (2012) 0.80
Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer (2015) 0.80
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. J Transl Med (2016) 0.79
Molecular markers in peripheral blood of Iranian women with breast cancer. Cancer Microenviron (2012) 0.79
SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Dig Dis Sci (2015) 0.78
MiR-1228 promotes breast cancer cell growth and metastasis through targeting SCAI protein. Int J Clin Exp Pathol (2015) 0.77
Loss of the BRCA1-interacting helicase BRIP1 results in abnormal mammary acinar morphogenesis. PLoS One (2013) 0.76
Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer. BMC Cancer (2015) 0.76
The role of c-Myc-RBM38 loop in the growth suppression in breast cancer. J Exp Clin Cancer Res (2017) 0.75
Circuits of cancer drivers revealed by convergent misregulation of transcription factor targets across tumor types. Genome Med (2016) 0.75
On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer. Oncotarget (2016) 0.75
Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells via downregulation of the epidermal growth factor receptor. Oncotarget (2016) 0.75
MYC is expressed in the stromal and epithelial cells of primary breast carcinoma and paired nodal metastases. Mol Clin Oncol (2015) 0.75
Inherited and acquired alterations in development of breast cancer. Appl Clin Genet (2011) 0.75
Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. Int J Cancer (2016) 0.75
Myc suppresses tumor invasion and cell migration by inhibiting JNK signaling. Oncogene (2017) 0.75
Expression Study and Clinical Correlations of MYC and CCAT2 in Breast Cancer Patients Iran Biomed J (2017) 0.75
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J (1997) 15.10
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett (1997) 12.43
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol (2000) 8.47
Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol (2005) 7.54
c-MYC: more than just a matter of life and death. Nat Rev Cancer (2002) 6.73
BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer (2004) 6.24
The c-Myc target gene network. Semin Cancer Biol (2006) 5.98
Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res (1999) 4.74
Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science (1991) 4.45
In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature (2000) 4.38
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med (1997) 4.33
HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J (2004) 4.26
Aberrant activation of notch signaling in human breast cancer. Cancer Res (2006) 3.92
The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem (1998) 3.67
Myc pathways provoking cell suicide and cancer. Oncogene (2003) 3.49
X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell (2003) 3.37
The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol (2006) 3.31
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene (2006) 3.27
Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A (2006) 2.92
Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol (1982) 2.89
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2001) 2.87
Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo. EMBO J (1996) 2.86
Risk models for familial ovarian and breast cancer. Genet Epidemiol (2000) 2.75
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci U S A (1986) 2.66
Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem (2003) 2.66
Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci U S A (2001) 2.55
BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet (1998) 2.55
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science (1999) 2.54
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res (2006) 2.52
BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A (1998) 2.50
Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nat Genet (2000) 2.19
Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol (2001) 2.15
BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A (1999) 2.10
The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet (1995) 2.02
BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc Natl Acad Sci U S A (1997) 2.02
The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem (2006) 1.96
Phylogenetic analysis of the human basic helix-loop-helix proteins. Genome Biol (2002) 1.96
Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci U S A (2005) 1.91
PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J (2001) 1.88
Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst (2002) 1.87
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst (1997) 1.87
Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor. J Biol Chem (2000) 1.86
The many faces of c-MYC. Arch Biochem Biophys (2003) 1.74
c-myc is a downstream target of the Smad pathway. J Biol Chem (2001) 1.74
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res (2005) 1.71
MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A (2006) 1.66
A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics (2001) 1.64
Control of biochemical reactions through supramolecular RING domain self-assembly. Proc Natl Acad Sci U S A (2002) 1.63
BRCA1 gene in breast cancer. J Cell Physiol (2003) 1.55
The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer (2006) 1.54
Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers. Nucleic Acids Res (1993) 1.53
Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res (2004) 1.52
c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol (2007) 1.50
Self-assembly properties of a model RING domain. Proc Natl Acad Sci U S A (2002) 1.46
Predominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol (2005) 1.30
Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol (2003) 1.27
A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem (2002) 1.25
Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med (2002) 1.22
BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene (1998) 1.21
Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol (2004) 1.20
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer (2004) 1.19
Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res (2003) 1.19
MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res (2004) 1.18
An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer (1998) 1.17
BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res (2005) 1.15
MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol (2006) 1.14
Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem (2006) 1.13
c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol (2005) 1.11
Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp Mol Pathol (2006) 1.10
Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. Clin Biochem (2001) 1.10
Identification of target genes of oncogenic transcription factors. Proc Soc Exp Biol Med (1999) 1.07
Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res (2002) 1.07
BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription. Proc Natl Acad Sci U S A (2000) 1.06
DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene. Nucleic Acids Res (2004) 1.04
c-myc amplifications in primary breast carcinomas and their local recurrences. J Clin Pathol (2006) 1.04
C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res (2003) 1.04
Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. Cytometry (2001) 1.01
C-myc oncogene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat (2002) 1.00
Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer (2001) 0.98
The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet (2006) 0.98
Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep (2005) 0.98
Rapid identification of key amino-acid-DNA contacts through combinatorial peptide synthesis. Chem Biol (2000) 0.98
Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett (2006) 0.98
PEG10 is a c-MYC target gene in cancer cells. Cancer Res (2006) 0.97
Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. Int J Cancer (1999) 0.95
Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. Exp Mol Pathol (2005) 0.95
Targeting oncogenes to improve breast cancer chemotherapy. Cancer Res (2006) 0.93
c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer (1999) 0.92
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2008) 7.65
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer (2007) 3.02
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 2.45
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res (2002) 2.25
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23
Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst (2013) 2.21
Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol (2010) 2.20
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol (2007) 2.16
Treatment of cancer in sub-Saharan Africa. Lancet Oncol (2013) 2.07
ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn (2012) 1.99
Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol (2006) 1.93
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol (2010) 1.90
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol (2008) 1.89
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet (2002) 1.80
Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am (2005) 1.76
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet (2010) 1.74
Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15. Hum Mutat (2010) 1.73
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res (2005) 1.71
MYC and Breast Cancer. Genes Cancer (2010) 1.66
Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol (2006) 1.60
Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology (2002) 1.58
Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: effect of ROI size and location. Med Phys (2004) 1.57
X-ray fluorescence microscopy reveals large-scale relocalization and extracellular translocation of cellular copper during angiogenesis. Proc Natl Acad Sci U S A (2007) 1.55
Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol (2011) 1.49
Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol (2005) 1.49
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun (2013) 1.43
Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res (2011) 1.43
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med (2011) 1.42
Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment. J Digit Imaging (2008) 1.41
Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis (2012) 1.38
Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J (2010) 1.32
Confronting genetic testing disparities: knowledge is power. JAMA (2005) 1.26
EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene (2003) 1.23
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat (2007) 1.22
How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol (2007) 1.21
"Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med (2006) 1.21
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control (2005) 1.20
Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev (2003) 1.20
MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res (2004) 1.18
Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat (2010) 1.17
The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol (2013) 1.16
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat (2013) 1.16
Concordance in histological and biological parameters between first and second primary breast cancers. Cancer (2010) 1.15
Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun (2013) 1.13
Genetic susceptibility to breast cancer. Rev Endocr Metab Disord (2007) 1.13
Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma (2012) 1.13
Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope (2002) 1.11
A genome-wide association study of breast cancer in women of African ancestry. Hum Genet (2012) 1.11
Translational integrity and continuity: personalized biomedical data integration. J Biomed Inform (2008) 1.09
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer (2007) 1.09
Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol (2003) 1.08
MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat (2012) 1.07
The effect of varying spectral resolution on the quality of high spectral and spatial resolution magnetic resonance images of the breast. J Magn Reson Imaging (2003) 1.06
Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer (2011) 1.05
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res (2011) 1.05
Fourier components of inhomogeneously broadened water resonances in breast: a new source of MRI contrast. Magn Reson Med (2004) 1.05
High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol (2006) 1.04
Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol (2009) 1.04
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res (2009) 1.04
Regulation of Tcf7l1 DNA binding and protein stability as principal mechanisms of Wnt/β-catenin signaling. Cell Rep (2013) 1.03
DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog (2011) 1.03
Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology (2009) 1.03
Incoming resident interest in global health: occasional travel versus a future career abroad? J Grad Med Educ (2011) 1.02
Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res (2014) 1.02
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res (2006) 1.01
Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer (2011) 1.01
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res (2009) 1.01
RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res (2008) 1.01
Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging (2006) 0.99
Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med (2005) 0.99
High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer (2012) 0.99
When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer (2012) 0.99
Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol (2010) 0.98
Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J (2012) 0.97